Fig. 1: CONSORT Flow diagram of the study. | npj Vaccines

Fig. 1: CONSORT Flow diagram of the study.

From: Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial

Fig. 1

Participants were enrolled from July 21, 2021 to December 22, 2021. The safety population included all participants who received at least one dose of the MVC-COV1901 vaccine or placebo. The per protocol set (PPS) population consisted of participants who received the two doses of MVC-COV1901 or placebo as scheduled, and were seronegative at baseline with anti-nucleocapsid (anti-N) antibodies negative at Visit 2 and Visit 6, and did not have a major protocol deviations. Detailed reasons for exclusion from the PPS can be found in Supplementary Table 2.

Back to article page